Bahl & Gaynor’s Sarepta Therapeutics SRPT Stock Holding History

Bahl & Gaynor’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,597	Closed	-$207K	–	343
2022 Q4	$207K	Buy	+1,597	New	+$185K	﹤0.01%	330

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bahl & Gaynor's SRPT Position: Q1 2023 in Review

Bahl & Gaynor sold out of Sarepta Therapeutics (SRPT) in Q1 2023, closing a stake of 1,597 shares — an estimated $207K sold.

Bahl & Gaynor first reported a position in SRPT in Q4 2022 and held it in 1 quarter. The position peaked at $207K in Q4 2022. 425 funds tracked by Wall St. Rank hold SRPT as of Q1 2023.

Bahl & Gaynor reported no remaining Sarepta Therapeutics position as of Q1 2023 after selling out during the quarter.
Bahl & Gaynor sold 1,597 Sarepta Therapeutics shares in Q1 2023, an estimated $207K.
Bahl & Gaynor first reported a position in Sarepta Therapeutics in Q4 2022 and held it in 1 quarter.
Bahl & Gaynor's Sarepta Therapeutics position peaked at $207K in Q4 2022.
425 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2023.

Based on Bahl & Gaynor's 13F filing for Q1 2023, filed 3 May 2023.